How did STE's revenue and expenses perform in Q1 2025 compared to previous quarters?

Steris (STE) experienced a notable increase in revenue and a slight improvement in expenses in Q1 2025 compared to the previous quarter, Q4 2024.

1. **Revenue Performance**:
- In Q1 2025, Steris reported a total revenue of $1.37 billion from continuing operations, which represents a 5.6% year-over-year increase.
- This growth was primarily driven by strong performances in the Healthcare and Applied Sterilization Technologies (AST) segments. Healthcare segment revenues rose by 7% to $976.0 million, while AST revenues improved by 10% to $258.1 million.
- Organic revenues at constant exchange rate (CER) showed a robust increase of 6% year-over-year.
2. **Expense Performance**:
- The adjusted operating margin for Q1 2025 expanded by 61 basis points to 18.1%, indicating improved profitability.
- The company's cash and cash equivalents decreased from $172.2 million at the end of Q2 2024 to $155.2 million in Q1 2025.
3. **Comparative Analysis**:
- Q1 2025's revenue growth of 5.6% was slightly lower than the 6% increase reported in Q3 2024.
- The adjusted EPS of $2.32 in Q1 2025 was in line with expectations and represented a 9.9% increase from the previous year.
- Net income for Q1 2025 was $173.6 million, up from $148.4 million in Q4 2024, indicating a strong financial performance.

|code|Ticker|Name|Date|Total Revenue|Total Expenses|market_code|
|---|---|---|---|---|---|---|
|STE|STE.N|STERIS|2024 Q2|1.238204E9||169|
|STE|STE.N|STERIS|2024 Q3|1.297724E9||169|
|STE|STE.N|STERIS|2024 Q4|1.116154E9||169|
|STE|STE.N|STERIS|2025 Q1|1.279502E9||169|

In conclusion, Steris demonstrated solid revenue growth and improved profitability in Q1 2025, driven by strong segmental performances, particularly in Healthcare and AST, which contributed to the company's overall financial strength.